CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 222 enrolled
Drug / intervention
Magnesium Sulfatedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03164304
NCT03164304Phase 4Completed
CompareCT.gov

Efficacy and Safety of One Gram Versus Two Grams Intravenous Maintenance Dose of Magnesium Sulfate in Women With Severe Pre-eclampsia: a Randomized Clinical Trial.

Assiut University·interventional·Posted May 23, 2017·Updated Apr 24, 2020

In Brief

A Phase 4 clinical trial evaluating Magnesium Sulfate for Severe Preeclampsia. Completed, enrolled 222 participants across 1 site.

Detailed Summary

Preeclampsia is commonly viewed as one of the hypertensive pregnancy disorders, which cover a spectrum of clinical presentations from chronic hypertension ( hypertension occurring prior to 20 weeks of gestation) and gestational hypertension (hypertension occurring after 20 weeks of gestation) To more severe forms, including preeclampsia, eclampsia (its convulsive form), and HELLP syndrome (hemolysis, elevated liver enzyme S, and low platelets)

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSevere Preeclampsia
CountriesEgypt
Collaborators--

Timeline

Phase 4CompletedFinished
201820192020202120222023202420252026
First PostedMay 23, 2017
Enrollment StartMay 30, 2017
Primary CompletionJan 30, 2020
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 9.1 years ago

Interventions

Magnesium Sulfatedrug

intravenous